Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 441-446

  Ku, Tsun Sheng N ^a,b   Palanisamy, Suresh K A ^a,b   Lee, Samuel A ^a,b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Amphotericin; Biofilms; Candida albicans; Caspofungin; Fluconazole; Tigecycline

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CASPOFUNGIN; FLUCONAZOLE; TIGECYCLINE; VANCOMYCIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG EFFECT; DRUG INHIBITION; DRUG SCREENING; FUNGAL METABOLISM; FUNGUS GROWTH; GROWTH INHIBITION; IN VITRO STUDY; METABOLIC ACTIVATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BIOFILMS; CANDIDA ALBICANS; DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MINOCYCLINE; VANCOMYCIN;

EID: 77957686648     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.034     Document Type: Article

References (35)

1. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond R.P. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
2. Fridkin S.K., Jarvis W.R. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996, 9:499-511.
3. Donlan R.M. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001, 33:1387-1392.
4. Donlan R.M. Biofilms and device-associated infections. Emerg Infect Dis 2001, 7:277-281.
5. Dougherty S.H. Pathobiology of infection in prosthetic devices. Rev Infect Dis 1988, 10:1102-1117.
6. Dasgupta M.K. Biofilms and infection in dialysis patients. Semin Dial 2002, 15:338-346.
7. Ramage G., Saville S.P., Thomas D.P., Lopez-Ribot J.L. Candida biofilms: an update. Eukaryot Cell 2005, 4:633-638.
8. Ramage G., Martinez J.P., Lopez-Ribot J.L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 2006, 6:979-986.
9. Costerton J.W., Cheng K.J., Geesey G.G., Ladd T.I., Nickel J.C., Dasgupta M., et al. Bacteria biofilms in nature and disease. Annu Rev Microbiol 1987, 41:435-464.
10. Hawser S.P., Douglas L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995, 39:2128-2131.
11. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
12. Medoff G., Kobayashi G.S., Kwan C.N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc Natl Acad Sci U S A 1972, 69:196-199.
13. Huppert M., Sun S.H., Vukovich K.R. Combined amphotericin B-tetracycline therapy for experimental coccidioidomycosis. Antimicrob Agents Chemother 1974, 5:473-478.
14. Beggs W.H., Sarosi G.A., Walker M.I. Synergistic action of amphotericin B and rifampin against Candida species. J Infect Dis 1976, 133:206-209.
15. Lew M.A., Beckett K.M., Levin M.J. Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B. J Infect Dis 1977, 136:263-270.
16. Lew M.A., Beckett K.M., Levin M.J. Combined activity of minocycline and amphotericin B in vitro against medically important yeasts. Antimicrob Agents Chemother 1978, 14:465-469.
17. Edwards J.E., Morrison J., Henderson D.K., Montgomerie J.Z. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob Agents Chemother 1980, 17:484-487.
18. Kuhn D.M., George T., Chandra J., Mukherjee P.K., Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002, 46:1773-1780.
19. Katragkou A., Chatzimoschou A., Simitsopoulou M., Dalakiouridou M., Diza-Mataftsi E., Tsantali C., et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008, 52:357-360.
20. El-Azizi M. Enhancement of the in vitro activity of amphotericin B against the biofilms of non-albicans Candida spp. by rifampicin and doxycycline. J Med Microbiol 2007, 57:645-649.
21. Miceli M.H., Bernardo S.M., Lee S.A. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 2009, 34:326-332.
22. Gillum A.M., Tsay E.Y., Kirsch D.R. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984, 198:179-182.
23. Ramage G., Lopez-Ribot J.L. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 2005, 118:71-79.
24. Chamilos G., Lewis R.E., Albert N., Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007, 51:2257-2259.
25. Melo A.S., Colombo A.L., Arthington-Skaggs B.A. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007, 51:3081-3088.
26. Wiederhold N.P. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis 2007, 20:574-578.
27. Messing B., Peitra-Cohen S., Debure A., Beliah M., Bernier J.J. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988, 12:185-189.
28. Bestul M.B., Vandenbussche H.L. Antibiotic lock technique: review of the literature. Pharmacotherapy 2005, 25:211-227.
29. Segarra-Newnham M., Martin-Cooper E.M. Antibiotic lock technique: a review of the literature. Ann Pharmacother 2005, 39:311-318.
30. Aslam S., Trautner B.W., Ramananthan V., Darouiche R.O. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007, 51:1556-1558.
31. Raad I., Hanna H., Jiang Y., Dvorak T., Reitzel R., Chaiban G., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007, 51:1656-1660.
32. Bookstaver P.B., Williamson J.C., Tucker B.K., Raad I.I., Sheretz R.J. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 2009, 43:210-219.
33. Aslam S., Trautner B.W., Ramanathan V., Darouiche R.O. Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia. Infect Control Hosp Epidemiol 2008, 29:894-897.
34. Pankey G., Tigecycline J Antimicrob Chemother 2005, 56:470-480.
35. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005, 41(Suppl. 5):S303-S314.